Key Points
- Orbimed Advisors director sold 47,814 shares on April 14 and, across filings from April 14–16, sold roughly 510,583 shares (~$22.9M), leaving them with about 3,482,888 shares (a ~1.35% ownership decrease, valued at ~ $155M).
- The trades were executed under a pre‑arranged Rule 10b5‑1 plan (which tempers opportunistic interpretations); Sionna recently posted an earnings beat (EPS -$0.46 vs. -$0.61), is trading above its 50/200‑day averages, has a ~$2.04B market cap, and an average analyst rating of "Moderate Buy" with a $50.57 target.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 47,814 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14. Following the sale, the director owned 3,482,888 shares in the company, valued at approximately $155,023,344.88. This trade represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
- On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
- On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54.
- On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30.
Sionna Therapeutics Trading Up 0.3%
Shares of SION opened at $45.24 on Friday. Sionna Therapeutics, Inc. has a twelve month low of $9.39 and a twelve month high of $46.10. The firm's fifty day simple moving average is $37.60 and its 200-day simple moving average is $38.23. The firm has a market capitalization of $2.04 billion, a price-to-earnings ratio of -23.20 and a beta of 3.01.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.15.
Key Headlines Impacting Sionna Therapeutics
Here are the key news stories impacting Sionna Therapeutics this week:
- Positive Sentiment: The company reported an earnings beat on March 2 (EPS -$0.46 vs. consensus -$0.61), which remains a supportive fundamental datapoint for sentiment and helps explain why shares are trading above their 50/200-day averages.
- Positive Sentiment: Despite the sales, the reporting director (Orbimed / Peter A. Thompson) continues to hold a sizable stake — roughly 3.0–3.5 million shares valued in the low hundreds of millions — signalling ongoing substantial insider ownership that can temper negative interpretations of the trades.
- Neutral Sentiment: The reported sales were executed under pre-arranged Rule 10b5-1 trading plans. That procedural detail reduces the extent to which the trades are viewed as opportunistic or based on undisclosed private information.
- Neutral Sentiment: Trading volume has been elevated (today’s intraday volume is well above the average), which may reflect the market reacting to the insider filings and could magnify short-term price moves.
- Negative Sentiment: Multiple director sales were filed for April 14–16 totaling about 510,583 shares across three transactions (approx. $22.9M at the reported average prices). Large, consecutive insider sell filings can create short-term downward pressure or investor concern even when done under 10b5-1 plans. SEC Filing: Insider Sales
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the stock. BTIG Research restated a "buy" rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. Citizens Jmp assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a "market outperform" rating and a $63.00 price objective on the stock. Raymond James Financial restated a "strong-buy" rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a report on Monday, January 5th. Weiss Ratings restated a "sell (e+)" rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Lifesci Capital upgraded shares of Sionna Therapeutics to a "strong-buy" rating in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $50.57.
Get Our Latest Stock Analysis on SION
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of SION. Goldman Sachs Group Inc. purchased a new position in shares of Sionna Therapeutics in the 1st quarter valued at $667,000. Woodline Partners LP purchased a new position in shares of Sionna Therapeutics in the 1st quarter valued at $837,000. Geode Capital Management LLC grew its position in shares of Sionna Therapeutics by 113.4% in the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company's stock valued at $5,020,000 after buying an additional 153,712 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $307,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sionna Therapeutics in the 2nd quarter valued at $118,000.
Sionna Therapeutics Company Profile
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
